Position in GLUE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,897,062
-$1,184,138 QoQ
Shares Held
78,391
-58.1% QoQ
Ownership
0.092%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#80
of 193 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GLUE Over Time
Shares Held
Position Value (USD)
Derivatives in GLUE
reported options exposure · as of Jun 30, 2026CallValue
$4,116,420
CallShares
170,100
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names. GLUE ranks #24 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
139,218 | $26,072,747 | |
| 2 | ABVX |
Abivax S.A.
|
163,644 | $21,807,199 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
493,664 | $19,104,796 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
312,846 | $17,901,048 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
441,808 | $17,234,930 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
272,214 | $11,060,054 | |
| 7 | KOD |
Kodiak Sciences Inc.
|
218,117 | $8,497,838 | |
| 8 | IMCR |
Immunocore Holdings plc
|
254,863 | $8,091,900 |
All Filings in GLUE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,897,062 | 78,391 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $4,116,420 | 170,100 | Call | Sole | 2026-08-14 | |
| 2026-03-31 | $3,081,200 | 187,307 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $976,566 | 62,281 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||